Bank of America upgraded BioCryst Pharmaceuticals, Inc. BCRX from Underperform to Neutral.
BioCryst Pharmaceuticals shares have surged 8.19 percent over the past 52 weeks, while the S&P 500 index has gained 11.18 percent in the same period.
Biocryst Pharmaceuticals shares closed at $9.78 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
